Compare GSK plc (GSK) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs YieldMax NVDA Option Income Strategy ETF — how do they compare? GSK plc trades at $52.61 (market cap $101.34B), while YieldMax NVDA Option Income Strategy ETF trades at $12.51. The key difference: GSK plc pays a 3.49% dividend while YieldMax NVDA Option Income Strategy ETF pays none, and GSK plc is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| GSK | NVDY | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $61.18 | $17.96 |
52-Week Low | $36.20 | $12.03 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
NVDY (YieldMax NVDA Option Income Strategy ETF) trades at $12.60, down 1.56% with a mixed technical outlook showing bullish overall signals but bearish moving averages. The ETF generates weekly income through NVIDIA option strategies, with recent distributions ranging from $0.10-$0.21 per share. Technical analysis indicates support at $12-$13 levels while fundamental metrics remain unavailable for this income-focused strategy.
The ETF offers high-income potential through systematic option selling on NVIDIA shares but sacrifices significant upside participation. Recent articles highlight the trade-off between income generation and missed NVIDIA gains, with the 1.09% management fee impacting returns. Key risks include NVIDIA volatility exposure and the strategy's capped upside during strong market moves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
